Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Research data from University of Iowa update understanding of bladder cancer
November 25th, 2008
"A randomized clinical trial conducted in Japan compared standard intravesical epirubicin alone with epirubicin plus 1 year of oral Lactobacillus casei strain Shirota in patients who had undergone resection of intermediate-risk, non-muscle-invasive bladder cancer," investigators in the United States report. "A statistically significant similar to 15% absolute reduction in long-term tumor recurrence was seen in the group that received the oral probiotic; however, as the dropout rate was nearly 3.5-fold greater in the probiotic group, and as neither the treating doctors nor their patients were blinded to the assigned treatment, uncertainty remains as to the reliability of...
Source: Cancer Weekly (2008-11-25)
|
